TALLAHASSEE, Fla., Nov. 16, 2026 /PRNewswire/ — Trulieve Cannabis Corp. (NYSE: TRLV) (“Trulieve” or “the Company”), a leading and top-performing medical cannabis company in the U.S., today announced that the company is set to join to the Russell 2000® and 3000® Indices as part of the semi-annual Russell Indexes reconstitution, according to a preliminary list published by FTSE Russell on Friday, November 13, 2026. Final index membership is scheduled to become effective after the market close on Friday, Dec 11, 2026.
“We are thrilled to join the Russell 2000® and 3000® Indices, following uplisting to the New York Stock Exchange and domestication to the United States,” said Trulieve Chief Executive Officer Kim Rivers. “This marks another major milestone for Trulieve, building on our inclusion in the S&P Total Market, S&P Completion, and Morningstar Total Stock Market indices earlier this year. Index inclusion raises awareness of Trulieve, ultimately leading to greater liquidity and access to institutional investors.”
The Russell 2000® Index is a leading benchmark for the small-cap segment of the U.S. equity market. The index is a subset of the Russell 3000® Index and is widely used by investment managers and institutional investors for index funds and as a benchmark for active investment strategies. According to FTSE Russell, approximately $12 trillion in assets are benchmarked to or invested in products based on the U.S. Russell Indexes.
Forward-Looking Statements
This news release includes forward-looking statements within the meaning of the Private Securities Litigation Reform Act of 1995. These forward-looking statements are subject to known and unknown risks, uncertainties, and other factors which may cause actual events, results, performance, or achievements of the Company to be materially different from those contained in the forward-looking statements. Risks and uncertainties include, without limitation, the risks and factors discussed under the heading “Risk Factors” in our Annual Report on Form 10-K for the year ended December 31, 2025 and in our periodic reports subsequently filed with the United States Securities and Exchange Commission and in the Company’s filings on SEDAR+ at www.sedarplus.ca. There can be no assurance that any forward-looking statements herein will prove to be accurate, and accordingly readers are advised to rely on their own evaluation of such risks and uncertainties and should not place undue reliance upon such forward-looking information and statements. Any forward-looking information and statements herein are made as of the date hereof and, except as required by applicable laws, the Company assumes no obligation and disclaims any intention to update or revise any forward-looking information and statements herein or to update the reasons that actual events or results could or do differ from those projected in any forward looking information and statements herein, whether as a result of new information, future events or results, or otherwise.
About Trulieve
Trulieve is an industry leading, vertically integrated cannabis company and multi-state operator in the U.S., with established medical marijuana operations in Florida, Georgia, Pennsylvania, and West Virginia. Driven by a core mission to expand access to cannabis, Trulieve serves customers with innovative, high-quality branded products and exceptional experiences. With scaled operations in attractive markets and targeted expansion through its hub strategy, Trulieve is poised for accelerated growth. Trulieve is listed on the NYSE under the symbol TRLV. For more information, please visit Trulieve.com.
Facebook: @Trulieve
Instagram: @Trulieve
X: @Trulieve
Investor and Media Contact
Christine Hersey, Chief Corporate Affairs and Strategy Officer
+1 (424) 202-0210
Christine.Hersey@Trulieve.com
SOURCE Trulieve Cannabis Corp.